Pharmax opens AED125-million pharmaceutical plant in Dubai Science Park
Pharmax Pharmaceuticals (Pharmax) has opened the first pharmaceutical manufacturing plant in Dubai Science Park as it looks to shorten the supply chain for generic medications for chronic conditions in the Middle East.
The AED125-million plant will have an annual production capacity of over 200 million tablet and capsule dosage forms, Madhukar Tanna, Chief Executive Officer of Pharmax, told Logistics Middle East.
See the video below:
“We are proud to be part of DSP’s vibrant business community, and are confident that now is the perfect time to launch Pharmax in the region,” he said. “Our company is fully aligned with the Dubai Industrial Strategy 2030 that, among other objectives, seeks to reduce the country’s reliance on imports of pharmaceutical products.”
Marwan Abdulaziz Janahi, managing director of Dubai Science Park and chairing member of the Pharmaceuticals and Medical Equipment Taskforce of the Dubai Industrial Strategy 2030, said: “Our region currently imports more than 80 per cent of pharmaceuticals from abroad. At the same time, technological advancements, an increase in R&D capacities and talent availability, state-of-the-art infrastructure, proximity to emerging markets, and a favourable policy framework present us with a unique opportunity to enhance our domestic manufacturing capabilities.”
The opening ceremony drew the participation of His Excellency Dr Amin Hussain Al Amiri, Assistant Undersecretary of Public Health Policy & Licensing at the Ministry of Health and Prevention, Dr Younis Kazim, Chief Executive Officer of Dubai Healthcare Corporation, Malek Al Malek, Group CEO of TECOM Group, Ahmad Tabari, Chairman of the Board of Directors at Pharmax, Lamia Berrada, Chairman of the Managing Board at Bottu Pharmaceuticals and Ayman Cheikh-Lahlou, Chief Executive Officer at Cooper Pharma.
The plant will focus on the manufacturing and commercialisation of pharmaceuticals that target chronic conditions prevalent in the Middle East. The factory is equipped with the latest European technology, meeting stringent global regulatory standards.
Established in 2016, the Dubai Industrial Strategy 2030 has identified the pharmaceuticals and medical equipment sector as one of six strategically important sectors for Dubai’s economy.
Positive forecasts predict that an increase in industrial capabilities will add AED160 billion (US$43.5 billion) to Dubai’s GDP, with the industrial sector growing by AED18 billion (US$4.9 billion).
Furthermore, the plan is expected to significantly enhance the UAE’s R&D capacities while adding 27,000 specialised jobs and AED15.8 billion (US$4.3 billion) to the country’s export sheet.
“We are now able to locally produce medication for cardiovascular diseases, psychiatric and neurological disorders, gastroenterological diseases, metabolic disorders such as hyperlipidaemia and diabetes, central nervous system diseases, bacterial and viral infectious diseases, respiratory illnesses, asthma and allergies, bone and joint inflammation disorders, and urological diseases,” said Tanna. “This will significantly reduce the dependence on imports of related products from abroad.”
Construction of the facility began in September 2015 as a joint venture between Al Ittihad Drug Store, a distributor of medicines in the UAE, and two of the largest pharmaceutical manufacturing companies in Morocco - Cooper Pharma and Bottu Pharmaceuticals.